Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy

Rossi, Renato; Monasterolo, Giorgio; Coco, Giuseppe; Silvestro, Luisa; Operti, D.

doi:10.1016/j.vaccine.2006.08.040

Cited by 57 publications

(40 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Im Gegensatz zu sIgE-Antikörpern stellen allergenspezifische IgG-Antikörper (sIgG) der Subklassen 1-4 in erster Linie eine physiologische Immunantwort auf "Fremdproteine" unterschiedlicher Allergenquellen dar. So wird bei chronischer Allergenexposition im Rahmen der SIT mit Allergenextrakten regelhaft ein bis zu 100-facher sIgG-Anstieg beobachtet, der insbesondere auf eine gesteigerte Synthese spezifischer IgG 4 -Antikörper zurückgeht [16,17]. Zunächst wurde die Hauptwirkung dieser von Cookson bereits 1935 als "blocking antibodies" beschriebenen Immunglobuline vorwiegend in einer kompetitiven Hemmung allergenspezifischer IgE-Antikörper durch Konkurrenz um das allergene Epitop ("antigen interception") gesehen [18,19].…”

Section: Allergenspezifische Igg-antikörperunclassified

Immunologische Verlaufsparameter unter spezifischer Immuntherapie

Ott

Wosnitza

2008

Hautarzt

View full text Add to dashboard Cite

In vivo-methods used for clinical follow-up control during specific immunotherapy (SIT) are associated with the risk of potentially severe reactions. As a safe diagnostic alternative, several in vitro-methods are currently available permitting the evaluation of immunomodulatory SIT effects. The basophil activation test, the lymphocyte transformation test and fluorescence immunoassays detecting allergen-specific IgG- and IgG4-antibodies have been utilized for this purpose. However, a reliable correlation of an immunological follow-up parameter with clinical efficacy of SIT has not been established. Therefore, further controlled studies are needed to evaluate the clinical usefulness of the described in vitro-techniques. In the future, a combination of different diagnostic methods defining sequential immunological modifications could lead to the identification of an in vitro profile characteristic of a successful SIT.

show abstract

Section: Allergenspezifische Igg-antikörperunclassified

Immunologische Verlaufsparameter unter spezifischer Immuntherapie

Ott

Wosnitza

2008

Hautarzt

View full text Add to dashboard Cite

show abstract

“…A variety of immunological changes have been reported following IT [6]. These include an increase in the allergen-specific IgG antibody [7], a reduction in the allergen-specific IgE antibody subsequent to transient increase [8], and a decrease in quantity and activity of basophils and mast cells [9]. Enhanced interferon (IFN)-c responses to allergen have been observed after grass pollen IT.…”

Section: Introductionmentioning

confidence: 99%

Immunological markers in allergic rhinitis patients treated with date palm immunotherapy

et al. 2012

View full text Add to dashboard Cite

show abstract

“…So far there is no consensus regarding the mechanism of successful SIT, but it is thought to involve a redressed Th1/ Th2 cell balance [17] by depressing the Th2 cellular response [interleukin (IL)-4, IL-5 and IL-13] in favour of a more Th1-like response [interferon (IFN)-g, IL-2 and tumour necrosis factor (TNF)-a], the induction of regulatory T cells [18] and formation of specific IgG, especially IgG4 antibodies [19][20][21][22].…”

Section: Introductionmentioning

confidence: 99%

Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children

Rosewich

Schulze

Eickmeier

et al. 2010

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummarySpecific immunotherapy (SIT) is a well-established and clinically effective treatment for allergic diseases. A pollen allergoid formulated with the T helper type 1 (Th1)-inducing adjuvant monophosphoryl lipid A (MPL) facilitates short-term SIT. Little is known about mechanisms of tolerance induction in this setting. In a prospective study, 34 patients allergic to grass pollen (25 male, nine female, median age 10·2 years) received a total of 44 SIT courses (20 in the first, 24 in the second) with MPL-adjuvanted pollen allergoids. Immunogenicity was measured by levels of specific immunoglobulin G (IgGgrass) and IgG4grass by antibody blocking properties on basophil activation, and by induction of CD4 + , CD25 + and forkhead box P3 (FoxP3 + ) regulatory T cells (Treg). Specific IgG and IgG4 levels increased only slightly in the first year of SIT. In the second year these changes reached significance (P < 0·0001). In keeping with these findings, we were able to show an increase of Treg cells and a decreased release of leukotrienes after the second year of treatment. In the first year of treatment we found little evidence for immunological changes. A significant antibody induction was seen only after the second course of SIT. Short-course immunotherapy with pollen allergoids formulated with the Th1-inducing adjuvant MPL needs at least two courses to establish tolerance.

show abstract

Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy

Cited by 57 publications

References 35 publications

Immunologische Verlaufsparameter unter spezifischer Immuntherapie

Immunologische Verlaufsparameter unter spezifischer Immuntherapie

Immunological markers in allergic rhinitis patients treated with date palm immunotherapy

Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children

Contact Info

Product

Resources

About